Treatment of asthma with fructose-1,6-diphosphate

Abstract

Fructose-1,6-diphosphate (FDP), a sugar-phosphate compound, can be useful in treating asthma, when administered as an inhalable drug, either by itself or as a component of a mixed formulation. On a cellular level, inhalable FDP appears to offer at least four beneficial effects for asthma sufferers: (1) it reduces histamine release by activated mast cells; (2) it suppresses production of oxygen free radicals by polymorphonuclear cells; (3) it helps suppress the activation and proliferation of T-lymphocytes; and, (4) it helps reduce the expression of interleukin compounds by T-lymphocytes. All four effects have been measured and shown to occur in animal and/or human tests, and these effects render FDP likely to help reduce and retard the progressive worsening of asthma that occurs in many sufferers. In addition, when tested in inhalable form on humans, FDP was shown to increase bronchial flow rates. All of these effects are beneficial, and can help asthma patients treated with FDP use asthma-control drugs which impose less stress on the user than more potent, aggressive asthma-control drugs.

Dependencies are inferred from the claim text.